Literature DB >> 21401576

Epitope specificity of myeloperoxidase antibodies: identification of candidate human immunodominant epitopes.

B F Bruner1, E S Vista, D M Wynn, J A James.   

Abstract

Anti-neutrophil cytoplasmic autoantibodies (ANCA) are a common feature of systemic vasculitides and have been classified as autoimmune conditions based, in part, on these autoantibodies. ANCA are subdivided further based on their primary target: cytoplasm (c-ANCA) or perinuclear region (p-ANCA). p-ANCAs commonly target myeloperoxidase (MPO), an enzyme with microbicidal and degradative activity. MPO antibodies are non-specific for any single disease and found in a variety of vasculitides, most commonly microscopic polyangiitis. Despite their prevalence, their role in human disease pathogenesis remains undefined. We sought to characterize the sequential antigenic determinants of MPO in vasculitis patients with p-ANCA. Of 68 patients with significant levels of p-ANCA, 12 have significant levels of MPO antibodies and were selected for fine specificity epitope mapping. Sequential antigenic targets, including those containing amino acids (aa) 213-222 (WTPGVKRNGF) and aa 511-522 (RLDNRYQPMEPN), were commonly targeted with a prevalence ranging from 33% to 58%. Subsequent analysis of autoantibody binding to the RLDNRYQPMEPN peptide was assessed using a confirmatory enzyme-linked immunosorbent assay format, with six patients displaying significant binding using this method. Antibodies against this epitope, along with four others (aa 393-402, aa 437-446, aa 479-488 and aa 717-726), were reactive to the heavy chain structure of the MPO protein. One epitope, GSASPMELLS (aa 91-100), was within the pro-peptide structure of MPO. B cell epitope prediction algorithms identified all or part of the seven epitopes defined. These results provide major common human anti-MPO immunodominant antigenic targets which can be used to examine further the potential pathogenic mechanisms for these autoantibodies.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21401576      PMCID: PMC3087928          DOI: 10.1111/j.1365-2249.2011.04372.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

1.  Anti-neutrophil cytoplasmic antibodies target sequential functional proteinase 3 epitopes in the sera of patients with Wegener’s granulomatosis.

Authors:  B F Bruner; E S Vista; D M Wynn; J B Harley; J A James
Journal:  Clin Exp Immunol       Date:  2010-11       Impact factor: 4.330

2.  Epitope analysis of myeloperoxidase-specific antineutrophil cytoplasmic autoantibodies (MPO-ANCA) in childhood onset Graves' disease treated with propylthiouracil.

Authors:  M Fujieda; K Suzuki; H Sato; M Hattori; N Wada; M Tsuchiya; N Okamoto; T Murata; M Matsudaira; M Shimizu; K Ohta; K Naruse; S Sugihara; H Wakiguchi
Journal:  Clin Nephrol       Date:  2005-06       Impact factor: 0.975

3.  BALLView: an object-oriented molecular visualization and modeling framework.

Authors:  Andreas Moll; Andreas Hildebrandt; Hans-Peter Lenhof; Oliver Kohlbacher
Journal:  J Comput Aided Mol Des       Date:  2006-02-10       Impact factor: 3.686

4.  Anti-native and recombinant myeloperoxidase monoclonals and human autoantibodies.

Authors:  M A Audrain; T A Baranger; N Moguilevski; S J Martin; A Devys; C M Lockwood; J Y Muller; V L Esnault
Journal:  Clin Exp Immunol       Date:  1997-01       Impact factor: 4.330

5.  Antineutrophil cytoplasmic antibodies induce human monocytes to produce oxygen radicals in vitro.

Authors:  S Weidner; W Neupert; M Goppelt-Struebe; H D Rupprecht
Journal:  Arthritis Rheum       Date:  2001-07

6.  A panel set for epitope analysis of myeloperoxidase (MPO)-specific antineutrophil cytoplasmic antibody MPO-ANCA using recombinant hexamer histidine-tagged MPO deletion mutants.

Authors:  K Tomizawa; E Mine; A Fujii; Y Y Ohashi; S Yamagoe; Y Hashimoto; A Ishida-Okawara; M Ito; M Tanokura; T Yamamoto; Y Arimura; T Nagasawa; S Mizuno; K Suzuki
Journal:  J Clin Immunol       Date:  1998-03       Impact factor: 8.317

7.  Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization.

Authors:  E C Hagen; M R Daha; J Hermans; K Andrassy; E Csernok; G Gaskin; P Lesavre; J Lüdemann; N Rasmussen; R A Sinico; A Wiik; F J van der Woude
Journal:  Kidney Int       Date:  1998-03       Impact factor: 10.612

8.  Studies to demonstrate inhibition of functional activity of neutrophil lysosomal enzymes with ANCA.

Authors:  L Chang; J Savige
Journal:  Adv Exp Med Biol       Date:  1993       Impact factor: 2.622

Review 9.  The role of myeloperoxidase in the pathogenesis of systemic vasculitis.

Authors:  A Rutgers; P Heeringa; J W Tervaert
Journal:  Clin Exp Rheumatol       Date:  2003 Nov-Dec       Impact factor: 4.473

10.  Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide.

Authors:  E A Emini; J V Hughes; D S Perlow; J Boger
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

View more
  6 in total

1.  Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis.

Authors:  Aleeza J Roth; Joshua D Ooi; Jacob J Hess; Mirjan M van Timmeren; Elisabeth A Berg; Caroline E Poulton; JulieAnne McGregor; Madelyn Burkart; Susan L Hogan; Yichun Hu; Witold Winnik; Patrick H Nachman; Coen A Stegeman; John Niles; Peter Heeringa; A Richard Kitching; Stephen Holdsworth; J Charles Jennette; Gloria A Preston; Ronald J Falk
Journal:  J Clin Invest       Date:  2013-03-15       Impact factor: 14.808

Review 2.  Mechanisms of vascular damage in ANCA vasculitis.

Authors:  David Massicotte-Azarniouch; Carolina A Herrera; J Charles Jennette; Ronald J Falk; Meghan E Free
Journal:  Semin Immunopathol       Date:  2022-03-07       Impact factor: 11.759

3.  Restricted myeloperoxidase epitopes drive the adaptive immune response in MPO-ANCA vasculitis.

Authors:  Meghan E Free; Katherine G Stember; Jacob J Hess; Elizabeth A McInnis; Olivier Lardinois; Susan L Hogan; Yichun Hu; Carmen Mendoza; Andrew K Le; Alex J Guseman; Mark A Pilkinton; Dante S Bortone; Kristen Cowens; John Sidney; Edita Karosiene; Bjoern Peters; Eddie James; William W Kwok; Benjamin G Vincent; Simon A Mallal; J Charles Jennette; Dominic J Ciavatta; Ronald J Falk
Journal:  J Autoimmun       Date:  2019-08-02       Impact factor: 7.094

4.  Neutrophil extracellular trap components in fibrinoid necrosis of the kidney with myeloperoxidase-ANCA-associated vasculitis.

Authors:  Masaharu Yoshida; Mariko Sasaki; Kentaro Sugisaki; Yutaka Yamaguchi; Michiyuki Yamada
Journal:  Clin Kidney J       Date:  2013-06

5.  Epitope analysis of anti-myeloperoxidase antibodies in patients with ANCA-associated vasculitis.

Authors:  Shen-Ju Gou; Peng-Cheng Xu; Min Chen; Ming-Hui Zhao
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

6.  Myeloperoxidase anti-neutrophil cytoplasmic antibody affinity is associated with the formation of neutrophil extracellular traps in the kidney and vasculitis activity in myeloperoxidase anti-neutrophil cytoplasmic antibody-associated microscopic polyangiitis.

Authors:  Masaharu Yoshida; Muneharu Yamada; Yasuyo Sudo; Tadasu Kojima; Tomohiro Tomiyasu; Noriko Yoshikawa; Takashi Oda; Michiyuki Yamada
Journal:  Nephrology (Carlton)       Date:  2016-07       Impact factor: 2.506

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.